Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 3c, Revenues Beat; Offers FY20 EPS Guidance

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $2.30, $0.03 better than the analyst estimate of $2.27. Revenue for the quarter came in at $2.13 billion versus the consensus estimate of $2.11 billion.

"In 2019 we continued to successfully execute our plan to reposition the company for success, driven by our global team's focus on our One ZB mission and culture," said Bryan Hanson, President and CEO of Zimmer Biomet. "We continued to invest for growth and drove improved performance in 2019, especially in the second half of the year. We are operating from a position of strength for 2020 and beyond. I am proud of the entire ZB team and their unyielding commitment to the ZB mission and bettering the lives of patients around the world."

GUIDANCE:

Zimmer Biomet Holdings sees FY2020 EPS of $8.15-$8.45, versus the consensus of $8.29.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Five Below (FIVE) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY27 Guidance
• Petco Health and Wellness (WOOF) Misses Q1 EPS by 6c